Cancer news from FierceBiotech
NewsA deluge of pre-ASCO data hits the market
As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...
Enzon spins off biotech ops into $150M enterprise
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
SPOTLIGHT: Array lands $80M financing deal
Deerfield Management will provide $80 million to Array BioPharma to fund its drug discovery work. Array is advancing new therapies for inflammatory diseases and cancer. Principal and interest of 6.5 Read more...
Pfizer builds plant, creates jobs in Ireland
Pfizer has finally confirmed earlier reports about its plan to Read more...
Optimistic Dendreon revs up second program
Dendreon is making bullish noises about its development efforts. The CMO of the Seattle biotech says that Provenge will deliver positive new data to the FDA on the delayed cancer therapy Provenge Read more...
In survival mode, Genta hunts for funds
NJ Biz examines Genta, which has gone into survival mode as it seeks a way to gain FDA approval of its lead cancer therapy, Genasense. The FDA turned thumb's down on the therapy in 2004, and the Read more...
Asuragen spins off new miRNA company
Austin-based Asuragen is spinning off its miRNA therapeutic intellectual property into a new company and seeding it with $3 million in cash. Working with Yale University researchers, Mirna will Read more...
ALSO NOTED: Dendreon shares jump on investment deal; Iomai in pact with Merck; Foundation antes millions for MS leads; and much
> Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
Avanti launches bionano company
Avanti Therapeutics launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee will use Avanti's drug delivery technology to enhance the performance of Read more...
SGX shares slide on report of early-stage toxicity
Shares of SGX Pharmaceuticals were sliding this morning on the news that its lead cancer therapy Read more...
| Press ReleasesPRESS RELEASE: Cancer-resistant mouse discovered Cancer-resistant mouse discovered LEXINGTON, Ky. (November 27, 2007) − A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky. The Read more... PRESS RELEASE: Genes That Both Extend Life And Protect Against Cancer Identified Genes That Both Extend Life And Protect Against Cancer Identified A person is 100 times more likely to get cancer at age 65 than at age 35. But new research reported today in the journal Read more... |
Get more Cancer coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight